| Patients . | Entire cohort, N = 34 . | Group A (visible), N = 22 . | Group B (invisible), N = 12 . | P-value . |
|---|---|---|---|---|
| Age (years) | 75 [67.5, 79.2] | 76 [67.50, 80.8] | 69 [66.5, 76.5] | 0.19 |
| Female sex | 15 (45) | 10 (46) | 5 (42) | 1.0 |
| NYHA class III and IV | 28 (82) | 18 (90) | 10 (83) | 0.86 |
| BSA (Dubois) | 1.79 [1.67, 1.99] | 1.8 [1.67, 1.97] | 1.79 [1.7, .2.06] | 0.56 |
| Normal sinus rhythm | 16 (47) | 10 (46) | 6 (50) | 0.71 |
| EuroSCORE II | 9 [5.1, 16] | 9 [6, 16] | 9.5 [3.2, 18] | 0.72 |
| STS-PROM | 5.5 [3.8, 10.6] | 5.6 [4.1, 10.6] | 5 [3.1, 10.6] | 0.54 |
| Functional indication for TMViV | 0.21 | |||
| Mitral insufficiency | 12 (35) | 9 (41) | 3 (25) | |
| Mitral stenosis | 12 (35) | 5 (22) | 7 (58) | |
| Combined mitral vitium | 9 (26) | 7 (32) | 2 (17) | |
| Trans-stent leak | 1 (3) | 1 (5) | ||
| Mitral valve annular size | ||||
| Area (cm2) | 6.94 [5.72, 7.4] | 6.95 [6.1, 7.27] | 6.80 [5.35, 9.5] | 0.80 |
| 3D-Perimeter (mm) | 95.5 [87.55, 100,3] | 95 [89.0, 96.6] | 101.6 [87.1, 118.1] | 0.11 |
| TMViV Combined with a TAVR procedure | 10 (29) | 5 (23) | 5 (42) | 0.22 |
| MV prosthesis implanted | ||||
| Sapien 3 | 32 (94) | 20 (91) | 12 (100) | 0.41 |
| Lotus | 2 (6) | 2 (9) |
| Patients . | Entire cohort, N = 34 . | Group A (visible), N = 22 . | Group B (invisible), N = 12 . | P-value . |
|---|---|---|---|---|
| Age (years) | 75 [67.5, 79.2] | 76 [67.50, 80.8] | 69 [66.5, 76.5] | 0.19 |
| Female sex | 15 (45) | 10 (46) | 5 (42) | 1.0 |
| NYHA class III and IV | 28 (82) | 18 (90) | 10 (83) | 0.86 |
| BSA (Dubois) | 1.79 [1.67, 1.99] | 1.8 [1.67, 1.97] | 1.79 [1.7, .2.06] | 0.56 |
| Normal sinus rhythm | 16 (47) | 10 (46) | 6 (50) | 0.71 |
| EuroSCORE II | 9 [5.1, 16] | 9 [6, 16] | 9.5 [3.2, 18] | 0.72 |
| STS-PROM | 5.5 [3.8, 10.6] | 5.6 [4.1, 10.6] | 5 [3.1, 10.6] | 0.54 |
| Functional indication for TMViV | 0.21 | |||
| Mitral insufficiency | 12 (35) | 9 (41) | 3 (25) | |
| Mitral stenosis | 12 (35) | 5 (22) | 7 (58) | |
| Combined mitral vitium | 9 (26) | 7 (32) | 2 (17) | |
| Trans-stent leak | 1 (3) | 1 (5) | ||
| Mitral valve annular size | ||||
| Area (cm2) | 6.94 [5.72, 7.4] | 6.95 [6.1, 7.27] | 6.80 [5.35, 9.5] | 0.80 |
| 3D-Perimeter (mm) | 95.5 [87.55, 100,3] | 95 [89.0, 96.6] | 101.6 [87.1, 118.1] | 0.11 |
| TMViV Combined with a TAVR procedure | 10 (29) | 5 (23) | 5 (42) | 0.22 |
| MV prosthesis implanted | ||||
| Sapien 3 | 32 (94) | 20 (91) | 12 (100) | 0.41 |
| Lotus | 2 (6) | 2 (9) |
Values are shown in median [IQR] or number (%). Apart from valve 3D-Perimeter, there was no statistically significant difference between the 2 groups.
BSA: body surface area; IQR: interquartile range; MV: mitral valve; NYHA: New York Heart Association; STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR: transcatheter aortic valve replacement; TMViV: transcatheter mitral valve-in-valve.
| Patients . | Entire cohort, N = 34 . | Group A (visible), N = 22 . | Group B (invisible), N = 12 . | P-value . |
|---|---|---|---|---|
| Age (years) | 75 [67.5, 79.2] | 76 [67.50, 80.8] | 69 [66.5, 76.5] | 0.19 |
| Female sex | 15 (45) | 10 (46) | 5 (42) | 1.0 |
| NYHA class III and IV | 28 (82) | 18 (90) | 10 (83) | 0.86 |
| BSA (Dubois) | 1.79 [1.67, 1.99] | 1.8 [1.67, 1.97] | 1.79 [1.7, .2.06] | 0.56 |
| Normal sinus rhythm | 16 (47) | 10 (46) | 6 (50) | 0.71 |
| EuroSCORE II | 9 [5.1, 16] | 9 [6, 16] | 9.5 [3.2, 18] | 0.72 |
| STS-PROM | 5.5 [3.8, 10.6] | 5.6 [4.1, 10.6] | 5 [3.1, 10.6] | 0.54 |
| Functional indication for TMViV | 0.21 | |||
| Mitral insufficiency | 12 (35) | 9 (41) | 3 (25) | |
| Mitral stenosis | 12 (35) | 5 (22) | 7 (58) | |
| Combined mitral vitium | 9 (26) | 7 (32) | 2 (17) | |
| Trans-stent leak | 1 (3) | 1 (5) | ||
| Mitral valve annular size | ||||
| Area (cm2) | 6.94 [5.72, 7.4] | 6.95 [6.1, 7.27] | 6.80 [5.35, 9.5] | 0.80 |
| 3D-Perimeter (mm) | 95.5 [87.55, 100,3] | 95 [89.0, 96.6] | 101.6 [87.1, 118.1] | 0.11 |
| TMViV Combined with a TAVR procedure | 10 (29) | 5 (23) | 5 (42) | 0.22 |
| MV prosthesis implanted | ||||
| Sapien 3 | 32 (94) | 20 (91) | 12 (100) | 0.41 |
| Lotus | 2 (6) | 2 (9) |
| Patients . | Entire cohort, N = 34 . | Group A (visible), N = 22 . | Group B (invisible), N = 12 . | P-value . |
|---|---|---|---|---|
| Age (years) | 75 [67.5, 79.2] | 76 [67.50, 80.8] | 69 [66.5, 76.5] | 0.19 |
| Female sex | 15 (45) | 10 (46) | 5 (42) | 1.0 |
| NYHA class III and IV | 28 (82) | 18 (90) | 10 (83) | 0.86 |
| BSA (Dubois) | 1.79 [1.67, 1.99] | 1.8 [1.67, 1.97] | 1.79 [1.7, .2.06] | 0.56 |
| Normal sinus rhythm | 16 (47) | 10 (46) | 6 (50) | 0.71 |
| EuroSCORE II | 9 [5.1, 16] | 9 [6, 16] | 9.5 [3.2, 18] | 0.72 |
| STS-PROM | 5.5 [3.8, 10.6] | 5.6 [4.1, 10.6] | 5 [3.1, 10.6] | 0.54 |
| Functional indication for TMViV | 0.21 | |||
| Mitral insufficiency | 12 (35) | 9 (41) | 3 (25) | |
| Mitral stenosis | 12 (35) | 5 (22) | 7 (58) | |
| Combined mitral vitium | 9 (26) | 7 (32) | 2 (17) | |
| Trans-stent leak | 1 (3) | 1 (5) | ||
| Mitral valve annular size | ||||
| Area (cm2) | 6.94 [5.72, 7.4] | 6.95 [6.1, 7.27] | 6.80 [5.35, 9.5] | 0.80 |
| 3D-Perimeter (mm) | 95.5 [87.55, 100,3] | 95 [89.0, 96.6] | 101.6 [87.1, 118.1] | 0.11 |
| TMViV Combined with a TAVR procedure | 10 (29) | 5 (23) | 5 (42) | 0.22 |
| MV prosthesis implanted | ||||
| Sapien 3 | 32 (94) | 20 (91) | 12 (100) | 0.41 |
| Lotus | 2 (6) | 2 (9) |
Values are shown in median [IQR] or number (%). Apart from valve 3D-Perimeter, there was no statistically significant difference between the 2 groups.
BSA: body surface area; IQR: interquartile range; MV: mitral valve; NYHA: New York Heart Association; STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR: transcatheter aortic valve replacement; TMViV: transcatheter mitral valve-in-valve.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
